Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation

Annals of Hematology

Volumn 81, Issue 6, 2002, Pages 343-346

  Henkes, M ^a   Martin, S ^a   Einsele, H ^b   Aulitzky, W E ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Allogeneic blood stem cell transplantation; Autologous blood stem cell transplantation; Chronic lymphocytic leukemia; Famciclovir; Hepatitis B virus infection; High dose chemotherapy; Lamivudine; Myeloablative radiochemotherapy

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BENDAMUSTINE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; FLUDARABINE; GANCICLOVIR; LAMIVUDINE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; DRUG USE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; LEUKAPHERESIS; LIVER INJURY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REACTIVATION; WHOLE BODY RADIATION;

2-AMINOPURINE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 0036935056     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0469-0     Document Type: Article

References (36)

1. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantations for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17:394-398
2. Liang RHS, Lok ASF, Lai CL, et al. (1990) Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270
3. Lau JY, Lai CL, Lin HJ, et al. (1989) Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73:911-917
4. Lau GK, Liang R, Chiu EK, et al. (1997) Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 19:795-799
5. Lau GK, Liang R, Wu PC, et al. (1998) Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 28:359-368
6. Strasser SI, McDonald GB (1999) Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 93:1127-1136
7. Lai CL, Ching CK, Tung AK, et al. (1997) Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244
8. Lai CL, Chien RN, Leung NWY, et al. (1998) A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339: 61-68
9. Jaeckel E, Manns MP (1997) Experience with lamivudine against hepatitis B virus. Intervirology 40:322-336
10. Bartholomeusz A, Groenen LC, Locarini SA (1997) Clinical experience with famciclovir against hepatitis B virus. Intervirology 40:337-342
11. Dienstag JL, Perrillo RP, Schiff ER, et al. (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661
12. Böker KH, Ringe B, Krüger M, et al. (1994) Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 57: 1706-1708
13. Krüger M, Tillmann HL, Trautwein C, et al. (1996) Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplant Surg 2:253-262
14. Main J, Brown JL, Howells G, et al. (1996) A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 3:211-215
15. ter Borg F, Smorenburg S, de Man RA, et al. (1998) Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43:2267-2270
16. Clark FL, Drummond MW, Chambers S, et al. (1998) Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 9:385-387
17. Picardi M, Selleri C, de Rosa G, et al. (1998) Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 21:1267-1269
18. Yeo W, Steinberg JL, Tam JS, et al. (1999) Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59:263-269
19. Maguire CM, Crawford DH, Hourigan LF, et al. (1999) Case report: lamivudine therapy for submassive hepatitic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 14:801-803
20. Al-Taie OH, Mork H, Gassel AM, et al. (1999) Prevention of hepatitis B flare-up during chemotherapy using lamivudine: a case report and review of the literature. Ann Hematol 78: 247-249
21. Ahmed A, Keeffe EB (1999) Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 94:249-251
22. Dienstag JL, Schiff ER, Wright TL, et al. (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263
23. Rostaing L, Henry S, Cisterne JM, et al. (1997) Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 64:1624-1627
24. Rayes N, Seehofer D, Bechstein WO, et al. (1999) Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 13:447-452
25. Wedemeyer H, Boker KH, Pethig K, et al. (1999) Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 68:1503-1511
26. Scullard GH, Smith CI, Merigan TC, et al. (1981) Effects of immunosuppressive therapy in chronic active hepatitis B. Gastroenterology 81:987-991
27. Davis GL, Hoofnagle JH (1987) Reactivation of chronic hepatitis B virus infection. Gastroenterology 92:2028-2031
28. Tipples GA, Ma MM, Fischer KP, et al. (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717
29. Honkoop P, Niesters HG, de Man RA, et al. (1997) Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 26:1393-1395
30. Bartholomew MM, Jansen RW, Jeffers LJ, et al. (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22
31. Hokoop P, de Man RA, Niesters HGM, Schalm SW (1998) Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 29:510-514
32. Melegari M, Scaglioni PP, Wands JR (1998) Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633
33. Wolters LMM, Honkoop P, Niesters HGM, de Man RA (1998) Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol 28:909-910
34. Colledge D, Locarnini S, Shaw T (1997) Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26:216-225
35. Korba BE (1996) In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 29:49-51
36. Myers RP, Swain MG, Urbanski SJ, Lee SS (2001) Reactivation of hepatitis B e antigen-negative chronic hepatitis in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol 15:599-603